Defining benchmark values for outcomes of comprehensive resection of primary retroperitoneal liposarcoma: a retrospective multicenter study
Fabio Tirotta(University Hospitals Birmingham NHS Foundation Trust), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Dimitri Tzanis(Université Paris Cité), Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Hayden Snow(Peter MacCallum Cancer Centre), Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Samuel Ford(University Hospitals Birmingham NHS Foundation Trust), Toufik Bouhadiba(Institut Curie), Kenneth Cardona(Emory University), Ferdinando Cananzi(Humanitas University), Marko Novak(Peter MacCallum Cancer Centre), John E. Mullinax(Moffitt Cancer Center), Valerie P. Grignol(Ohio State University Hospital), S. Valeri, Chandrajit P. Raut(Dana-Farber Cancer Institute), Sylvie Bonvalot(Dana-Farber Cancer Institute), D. Strauß(Royal Marsden Hospital), Markus Albertsmeier(LMU Klinikum), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Mark Fairweather(Brigham and Women's Hospital), James Hodson(University Hospitals Birmingham NHS Foundation Trust), Andrew Hayes(Royal Marsden NHS Foundation Trust), Winan J. van Houdt(Dutch Cancer Society), Michelle Wilkinson(Royal Marsden Hospital), David Gyorki(The University of Melbourne), Jacek Skoczylas(The Maria Sklodowska-Curie National Research Institute of Oncology), Jason K. Sicklick(University of California San Diego)
Cited by 6
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k